209 related articles for article (PubMed ID: 36978917)
1. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
Freire Boullosa L; Van Loenhout J; Flieswasser T; Hermans C; Merlin C; Lau HW; Marcq E; Verschuuren M; De Vos WH; Lardon F; Smits ELJ; Deben C
Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978917
[TBL] [Abstract][Full Text] [Related]
2. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.
Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C
Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801
[TBL] [Abstract][Full Text] [Related]
3. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma.
Van Loenhout J; Freire Boullosa L; Quatannens D; De Waele J; Merlin C; Lambrechts H; Lau HW; Hermans C; Lin A; Lardon F; Peeters M; Bogaerts A; Smits E; Deben C
Cells; 2021 Oct; 10(11):. PubMed ID: 34831159
[TBL] [Abstract][Full Text] [Related]
4. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
[TBL] [Abstract][Full Text] [Related]
5. Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model.
Freire Boullosa L; Van Loenhout J; Hermans C; Lau HW; Merlin C; Marcq E; Takhsha FS; Martinet W; De Meyer GRY; Lardon F; Smits ELJ; Deben C
Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559255
[TBL] [Abstract][Full Text] [Related]
6. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition.
Deben C; Boullosa LF; Fortes FR; De La Hoz EC; Le Compte M; Seghers S; Peeters M; Vanlanduit S; Lin A; Dijkstra KK; Van Schil P; Hendriks JMH; Prenen H; Roeyen G; Lardon F; Smits E
J Exp Clin Cancer Res; 2024 Mar; 43(1):88. PubMed ID: 38515178
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
8. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
Gao Y; Chen MK; Chu YY; Yang L; Yu D; Liu Y; Hung MC
Am J Cancer Res; 2021; 11(1):236-250. PubMed ID: 33520371
[TBL] [Abstract][Full Text] [Related]
9. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
[TBL] [Abstract][Full Text] [Related]
10. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
11. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
13. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
[TBL] [Abstract][Full Text] [Related]
14. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
16. Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels.
Cui XY; Park SH; Park WH
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014444
[TBL] [Abstract][Full Text] [Related]
17. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer.
Saha A; Zhao S; Chen Z; Georgiou G; Stone E; Kidane D; DiGiovanni J
Mol Ther; 2021 Feb; 29(2):775-787. PubMed ID: 33091613
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.
Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T
PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042
[TBL] [Abstract][Full Text] [Related]
20. TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin.
Xiaobo C; Majidi M; Feng M; Shao R; Wang J; Zhao Y; Baladandayuthapani V; Song J; Fang B; Ji L; Mehran R; Roth JA
Sci Rep; 2016 Nov; 6():35741. PubMed ID: 27845352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]